Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to give their consent to take part and are expected to complete all required visits and procedures.
• Adults aged 18 to 70 years old (inclusive), of any gender.
• People who have been diagnosed with acute myeloid leukaemia (AML) — a type of blood cancer — that has come back after treatment or has not responded to standard treatment, based on specific medical guidelines.
• People whose leukaemia cells have tested positive for a specific protein marker called CLL-1 on at least 50% of the abnormal cells, confirmed by a laboratory test.
• People who have mostly recovered from side effects of previous treatments, with only mild issues remaining (confirm with trial site).
• People who are generally well enough to carry out everyday activities (rated 0 or 1 on a standard medical scale) and whose life expectancy is more than 3 months.
• People whose liver, kidneys, heart, and blood are functioning within specific acceptable ranges as measured by blood tests and heart scans (confirm with trial site for exact values).
• Women who are not able to become pregnant — for example, due to surgical removal of the uterus or ovaries, having had their tubes tied, or having gone through menopause for at least 1 year.
• Women who could become pregnant but have a negative pregnancy test at the start of the trial and agree to use an approved contraceptive method throughout the trial and for 1 year after the last treatment.
• Men who could father a child and agree to use barrier contraception or abstain from sex until 1 year after the last treatment.

Who may not be able to join:

• People who have been diagnosed with a specific subtype of leukaemia called acute promyelocytic leukaemia.
• People who have had another type of cancer within the past 3 years, with some exceptions for certain treated skin, cervical, thyroid, prostate, or breast cancers (confirm with trial site).
• People who have signs that the leukaemia has spread to the brain or nervous system.
• People who test positive for certain infections, including hepatitis B (with active virus detected), hepatitis C, HIV, cytomegalovirus (CMV), Epstein-Barr virus (EBV), or syphilis.
• People who have a history of serious allergic reactions, or who are known to be allergic to any ingredients in the trial treatments, including products derived from mice or foreign proteins.
• People with serious heart conditions, such as severe irregular heartbeat, unstable chest pain, a recent large heart attack, severe heart failure, or uncontrolled high blood pressure.
• People who have previously had an organ transplant or are being planned for one (bone marrow/stem cell transplants are excluded from this rule).
• People who currently have or have had graft-versus-host disease (a condition that can occur after a stem cell transplant where donor cells attack the body).
• People who have had a stem cell transplant within the 6 months before joining the trial.
• People with active autoimmune or inflammatory diseases affecting the nervous system, or active serious brain conditions (confirm with trial site for examples).
• People who have a cancer-related emergency — such as a blockage, severe infection-related complications, or other urgent conditions — that needs immediate treatment before the trial can begin.
• People who have an active infection that is not controlled and is being treated with antibiotics or antifungal/antiviral medicines.
• People who have had major surgery within 4 weeks before starting the trial's preparation treatment, or whose surgical wounds have not yet fully healed.
• People with a severe mental illness.
• People who have recently received certain blood-stimulating medications (such as G-CSF or GM-CSF) within 1–2 weeks before the blood collection step of the trial, as these may affect how the treatment is prepared.
• People who have been taking steroid tablets or immunosuppressant medicines within 2 weeks before the blood collection step (inhaled or skin-applied steroids may be acceptable — confirm with trial site).
• People who have received a live or weakened-virus vaccine within 4 weeks before the trial screening visit.
• People with alcohol dependency or a history of substance misuse.
• People who have taken part in another clinical trial within the past 3 months.
• People who have previously received any CAR-T cell therapy or other cell-based therapy.
• People who, in the treating doctor's judgement, have any other medical condition that would make participation unsafe.

Important: Always verify eligibility with the trial site directly before applying.